drugset / Trial / NCT06946680
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
Phase 1
Not yet recruiting
24 enrolled
University of Florida
American Brain Tumor Association · collabFlorida Department of Health, Live Like Bella · collabSt. Baldrick's Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)
Timeline
- Start
- 2026-07
- Primary completion
- 2030-12
- Completion
- 2045-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 8R-70CAR T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | 8R-70CAR T cells | Cell therapy | 1e+08 cells/kg | Intravenous |